By elucidating the mechanisms by which CD56 and PSA-CD56 influence ccRCC progression, we hope to contribute to the development of targeted therapies and improved diagnostic strategies for patients with ccRCC. The gene discussed is NCAM1; the disease is nonpapillary renal cell carcinoma.